A cohort study on the effects of Baitouweng decoction combined with drugs and endoscopy on clinical symptoms, immune level, and long- term prognosis in patients with ulcerative colitis

Abstract

Objective A case-control study was carried out to research the effects of Baitouweng decoction combined with drugs and endoscopy on clinical symptoms, immune level, and long-term prognosis of patients with ulcerative colitis (UC). Methods From March 2019 to March 2022, 100 patients with UC cured were arbitrarily divided into control and study groups in our hospital. The former group was cured with general treatment according to diagnosis and treatment and Mesalamine Rectal Enema at the same time. The effective rate was calculated. The syndrome scores, immunoglobulin A (IgA), immunoglobulin G (IgG), immunoglobulin M (IgM) levels, enteroscopy score, and colon pathology score were compared before and after treatment. Results There was a 96.00% resultful rate in the study group, while the resultful rate in the control group was 76.00%. The study group achieved a higher resultful rate (P < 0.05). After 3 months of treatment, the total score of abdominal pain, diarrhea, abdominal distension, acute weight, purulent and bloody stool, fatigue, addiction, and TCM syndrome decreased noticeably. The research group's TCM syndrome scores were considerably lower (P < 0.05). The score of colonoscopy and colon pathology in the study group was lower (P < 0.05). And the levels of IgA, IgM, and IgG in the study group were lower (P < 0.05). In the control group, intestinal obstruction occurred in 4 cases, rectal canceration in 6 cases, and colonic polyp in 2 cases. The total incidence of complications was 24.00%. There was 1 case of intestinal obstruction, 2 cases of rectal canceration, and 1 case of colonic polyp with a total of 8.00% complications. Complication rates in the study group were noticeably lower (P < 0.05). Conclusion Baitouweng decoction combined with medicine and endoscopy has a noticeable clinical effect on patients with UC, which can not only effectively enhance the clinical symptoms and intestinal mucosa and histopathology of patients with UC, but also noticeably strengthen the recovery of immune function of patients with UC.